SMAA yields 20000000.00% · ABBV yields 3.06%● Live data
📍 SMAA pulled ahead of the other in Year 1
Combined, SMAA + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SMAA + ABBV for your $10,000?
SMA Alliance, Inc. provides marketing and advertising solutions. It offers Internet focused lead generator, which drives live buyers to retailers through conversion of individual online product interest into live buyers soliciting purchase from retailers. The company focuses on the automobile industry, providing automobile retailers buying demand on a daily basis through application of proprietary technology and managed systems. Its services include used car classified posting; new car inventory classified posting; search engine saturation by producing and hosting micro/mobile sites and mobile apps; creation, customization, or clean up of dealership professional's social media pages; enhances the visibility of a dealership's news and events to search engines, as well as builds links for dealership Website; and self service classified posting. The company's services also comprise sales, phone, and Internet training on site or on demand; generating automotive credit leads for dealership from dealership specific inventory; generating credit filter leads; and call center services for the fulfillment of lead generation campaigns. It serves as a marketing and advertising vendor to retailers primarily in the automobiles, real estate, employment recruitment, travel, and government sectors. SMA Alliance, Inc. was incorporated in 1969 and is based in Newport News, Virginia.
Full SMAA Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.